Send to

Choose Destination
J Clin Pharmacol. 2009 Aug;49(8):947-56. doi: 10.1177/0091270009337509.

Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).

Collaborators (201)

Xu YS, Gu DF, Jia X, Chen Z, Sun JL, Chen J, Yu XH, Wang JH, Wang N, Zheng RP, Zhang SH, Liu CX, Sun LH, Zhao YC, Lin Y, Huang JB, Hu DY, Yang XC, Liu YZ, Gao MM, Zhang P, Deng CX, Liu Y, Li ZQ, Shi YQ, Hu TS, Chen YZ, Tan S, Zhao WR, Deng GL, Huang WJ, Zhang JC, Yu H, Shi QS, Wang XZ, Jiang B, Pan XR, Li L, Bu PL, Shu MQ, Xu QL, Zhang JH, Ding WH, Li L, Yang JJ, Su JL, Zhao WD, Liu X, Li LJ, Yang JF, Wang QS, Huang TG, Li LF, Zhou LJ, Guo JX, Li WH, Li ZP, Zhang XG, Peng XM, An YW, Shu J, Ma LT, Ge H, Zhang MJ, Lv ZR, Li JH, Yang JW, Zhang L, Cheng YL, Chen JG, Zhou CW, Zhang HH, Huang YL, Qu XF, LI JJ, Guo H, Wang GX, Hao SZ, Li SJ, Chang HS, Zhou SM, Liang HQ, Cao SJ, Liu JG, Yang J, Zhao MY, Lv Y, Xu SL, Wang ZL, Zhao SP, Li XP, Luo XL, Li YP, Lei Y, Fan SQ, Wang LH, Zhao LJ, Zhao YC, Xue SW, LI J, Xu SY, Cao YG, Tong BG, Wang W, Xu SK, Jing XF, Wang CH, Tang BX, Bai H, Li L, Liu Y, Li YP, Mei F, Yuan KZ, Zhang Y, Sun YR, Chen L, Xue SR, Wang JP, Li B, Liu ZM, Shen LH, Liang JR, Zhang Y, Song YL, Sun YM, Wan Z, Xu YH, Zhang WJ, Mu RQ, Li KQ, Wei YP, Wang SM, Fan YJ, An KY, Guo J, Li AP, Zeng DY, Huo HY, Chen Y, Song LX, Jiang BQ, Guo DJ, Chen H, Li L, Yin YQ, Mao YM, Miao L, Guo YJ, Li SJ, Cui SS, Diao Q, You XM, Jiang B, Zhu LT, Liu JM, Fang L, Lin SG, Chen LY, Huang WH, Zheng ZG, Ke YN, Wang Y, Wang QS, Liang H, Jia RY, Wang T, Liu CX, Geng QJ, Duan BX, Fang CQ, Wang JY, Chang ZW, Qi Y, Wang X, He WS, Ye P, Liu YC, Li CY, Ye JJ, He BX, Zhang XY, Hong XF, Shi RG, Wei WL, Sun JJ, Li ZC, Zhang XJ, He P, Gao W, He Y, Zhang HB, Li ND, He XN, Chen GL, Wang JL, Liang GF, Dai GZ, Wang Q, Jin HY, Wang S.

Author information

Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, People's Republic of China.


Coronary heart disease, hypertension, and dyslipidemia are highly prevalent and commonly coexist in people who are middle-aged and older. Previous data suggested that lowering cholesterol concentrations in individuals at high risk of cardiovascular disease improved clinical outcomes. Xuezhikang, a partial extract of red yeast rice containing statin, has a marked impact on lipids. The purpose of this study, therefore, was to evaluate the impact of Xuezhikang on reducing cardiovascular events and mortality in elderly Chinese hypertensive patients with a history of myocardial infarction (MI) enrolled in the Chinese Coronary Secondary Prevention Study. In this randomized trial, 1530 elderly hypertensive patients (> or = 65-years-old) with previous MI were assigned either to placebo (n = 758) or to Xuezhikang (n = 772) daily for an average of 4.5 years. The primary endpoint was recurrent coronary events; the secondary endpoint was all-cause mortality and other clinical events, including adverse effects. There were 68 cases of coronary events (8.8%) detected in the Xuezhikang group and 108 cases (14.3%) in the placebo group (38.2% risk reduction by Xuezhikang therapy). Death from coronary heart disease (CHD) totaled 49 cases in the Xuezhikang group (6.4%) and 68 cases in the placebo group (9.0%), indicating that Xuezhikang significantly decreased the risk of CHD death by 29.2%. Our study demonstrated that Xuezhikang therapy could effectively and safely reduce cardiovascular events and all-cause death in Chinese elderly hypertensive patients with previous MI. This finding may have an important implication for the treatment of elderly hypertensive patients with CHD.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center